Jianfeng Group Lin2017 -020 (Announcement on the Senior Management of the Company Receiving the Decision on Administrative Supervision Measures of Zhejiang Securities Regulatory Bureau)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2017-020
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Senior Management of the Company Receiving
Zhejiang Securities Regulatory Bureau's Decision on Administrative Supervision Measures The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Deputy General Manager of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company" and "Jianfeng Group") Mr. Zhang Fengliang received the "Decision on Administrative Supervision Measures" (No. 35 54 ) of Zhejiang Regulatory Bureau of China Securities Regulatory Commission on 2017 , , , August 30, , 11 (decision on Measures to Issue a Warning Letter to Zhang Fengliang, hereinafter referred to as "decision" ) , the main contents are as follows: "Zhang fengliang, you bought shares 2200
of Zhejiang Jianfeng group co., ltd. on2017 7 April 17 , after 2017 7 February 18 sold the company's stock 500 shares. As a senior manager of the company, your act of selling the company's stock within six months after you bought it violates Article 47 of the Securities Law. In addition, you sold 500 shares of the company without disclosing the reduction plan in advance, which also violated the relevant provisions of the" Certain Provisions on Shareholding Reduction of Shareholders of Listed Companies, Directors and Supervisors "(CSRC Announcement [2017 ] 9 ). In view of the fact that you have taken timely measures to conduct self-examination and self-correction without serious impact, and the board of directors of the company has issued an apology announcement for this incident on 2017
7 21 , our bureau has decided to take supervision and management measures to issue a warning letter to you and record it in the integrity file of the securities and futures market. You should seriously learn lessons, strengthen the study of securities laws and regulations, strictly regulate the buying and selling of shares of listed companies, and prevent such acts from happening again. If you are dissatisfied with these supervision and management measures, you can file an application for administrative reconsideration with the China Securities Regulatory Commission within 60
days from the date of receipt of this decision, or you can file a lawsuit in a people's court with jurisdiction within6 months from the date of receipt of this decision. During the period of reconsideration and litigation, the above-mentioned supervision and management measures shall not be suspended." The company will strictly follow the requirements of the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission to urge Mr. Zhang Fengliang to earnestly learn lessons and strengthen the study of securities laws and regulations; at the same time, the company's board of directors has notified all directors, supervisors, and senior management of the company of this matter. Personnel require all directors, supervisors, and senior managers of the company to take this as a warning and strengthen their study of laws and regulations such as the Securities Law and regulations, strengthen the management of securities accounts, strictly regulate the purchase and sale of company stocks, and prevent the recurrence of such matters.
is hereby announced.Board of Directors of Zhejiang Jianfeng Group Co., Ltd.2017
8
September 11
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page